FIGURE 1




FIGURE 2





FIGURE 3


Part 1: DLT Assessment (N~6)
Part 2: Further assess safety, tolerability and explore anti-tumor activity
Stage IIIB/IV NSCLC: No Prior Therapy
NSCLC Arm C
nab-paclitaxel/carboplatin x 4 + nivolumab starting cycle 1
NSCLC Arm C Expansion (N~14)
NSCLC Arm C
nab-paclitaxel/carboplatin x 4 + nivolumab starting cycle 3
NSCLC Arm D Expansion (N~14)